60 related articles for article (PubMed ID: 10874382)
1. Probabilistic sensitivity analysis in cost-effectiveness. An application from a study of vaccination against pneumococcal bacteremia in the elderly.
Whang W; Sisk JE; Heitjan DF; Moskowitz AJ
Int J Technol Assess Health Care; 1999; 15(3):563-72. PubMed ID: 10874382
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people.
Sisk JE; Moskowitz AJ; Whang W; Lin JD; Fedson DS; McBean AM; Plouffe JF; Cetron MS; Butler JC
JAMA; 1997 Oct 22-29; 278(16):1333-9. PubMed ID: 9343464
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of an antimicrobial stewardship team on bloodstream infections: a probabilistic analysis.
Scheetz MH; Bolon MK; Postelnick M; Noskin GA; Lee TA
J Antimicrob Chemother; 2009 Apr; 63(4):816-25. PubMed ID: 19202150
[TBL] [Abstract][Full Text] [Related]
5. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
Hubben GA; Bos JM; Glynn DM; van der Ende A; van Alphen L; Postma MJ
Vaccine; 2007 May; 25(18):3669-78. PubMed ID: 17360082
[TBL] [Abstract][Full Text] [Related]
6. [Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis].
Postma MJ; Heijnen ML; Beutels P; Jager JC
Ned Tijdschr Geneeskd; 2002 May; 146(18):855-9. PubMed ID: 12038224
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.
Postma MJ; Heijnen ML; Beutels P; Jager JC
Expert Rev Vaccines; 2003 Aug; 2(4):477-82. PubMed ID: 14711333
[TBL] [Abstract][Full Text] [Related]
8. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
Mangtani P; Roberts JA; Hall AJ; Cutts FT
Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries.
Ament A; Baltussen R; Duru G; Rigaud-Bully C; de Graeve D; Ortqvist A; Jönsson B; Verhaegen J; Gaillat J; Christie P; Cifre AS; Vivas D; Loiseau C; Fedson DS
Clin Infect Dis; 2000 Aug; 31(2):444-50. PubMed ID: 10987703
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
Melegaro A; Edmunds WJ
Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
[TBL] [Abstract][Full Text] [Related]
11. New vaccines against otitis media: projected benefits and cost-effectiveness.
O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
[TBL] [Abstract][Full Text] [Related]
12. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs.
Brisson M; Edmunds WJ
Med Decis Making; 2006; 26(5):434-46. PubMed ID: 16997923
[TBL] [Abstract][Full Text] [Related]
13. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
Hung HF; Chen TH
Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence.
Wu JM; Siddiqui NY; Amundsen CL; Myers ER; Havrilesky LJ; Visco AG
J Urol; 2009 May; 181(5):2181-6. PubMed ID: 19296983
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of influenza and pneumococcal vaccinations among elderly people in Japan.
Cai L; Uchiyama H; Yanagisawa S; Kamae I
Kobe J Med Sci; 2006; 52(3-4):97-109. PubMed ID: 16855372
[TBL] [Abstract][Full Text] [Related]
16. [Vaccination of the elderly against pneumococcal disease is cost-efficient. Mass vaccination of all aged 65 and over is recommended].
Ortqvist A; Jönsson B; Baltussen R; Ament A
Lakartidningen; 2000 Nov; 97(45):5120-5. PubMed ID: 11116891
[TBL] [Abstract][Full Text] [Related]
17. Early assessment of the likely cost-effectiveness of a new technology: A Markov model with probabilistic sensitivity analysis of computer-assisted total knee replacement.
Dong H; Buxton M
Int J Technol Assess Health Care; 2006; 22(2):191-202. PubMed ID: 16571195
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of Haemophilus influenzae type B vaccination in Indonesia: a cost-effectiveness analysis.
Broughton EI
J Public Health (Oxf); 2007 Dec; 29(4):441-8. PubMed ID: 17875589
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps.
Vold Pepper P; Owens DK
Clin Infect Dis; 2000 Jan; 30(1):157-64. PubMed ID: 10619745
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
Bergman A; Hjelmgren J; Ortqvist A; Wisløff T; Kristiansen IS; Högberg LD; Persson KM; Persson U
Scand J Infect Dis; 2008; 40(9):721-9. PubMed ID: 18712627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
